$MRNA: Here's Why the Post-Pandemic World May Be Even Better for This Vaccine Maker

During Moderna’s recent research and development day, CEO Stéphane Bancel said that “we are preparing for multiple product launches globally.”

There are three that may be very close, and they’re outside of the coronavirus program. So, they may not only offer fresh revenue sources, they will also expand Moderna’s business beyond one specialty.

Moderna’s investigational vaccines for flu, respiratory syncytial virus (RSV), and cytomegalovirus (CMV) are each in phase 3 trials. Bancel has said that if all goes smoothly, the flu and RSV candidates may reach commercialization in the coming two to three years.

$MRNA daily, weekly, and monthly charts